Armetheon, a privately held speciality pharmaceutical company developing small molecule drugs for cardiovascular diseases, has appointed Andrew Lam as Vice President of Product Development.
Lam has more than 27 years of experience in pharmaceutical product development. At Armetheon, he will lead CMC development and pharmaceutical operations and be a key member of the company's core team responsible for seeking approval in the US for tecarfarin, a novel oral anticoagulant in late-clinical stage development.
Prior to assuming his full-time position as Vice President of Product Development, Lam was a consultant to Armetheon. Before this, he was Vice President of Product Development at Altheos. Previously, he was Executive Director of Formulation and CMC for Exelixis.
Lam began his career at ALZA Corporation, a Johnson & Johnson company, where he attained positions of increasing responsibility including Senior Director, Head of Liquid OROS Technology Development.
